Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (NURPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nurpf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Neuren Pharmaceuticals LimitedYou NURPF | $1.2B | 55.88x | — | $0.24 |
 Anebulo Pharmaceuticals, Inc. ANEB | $15M | N/A | — | -$0.25 |
 Assembly Biosciences, Inc. ASMB | $375M | N/A | — | -$0.55 |
 Cerevel Therapeutics Holdings, Inc. CERE | $8.2B | N/A | — | -$2.67 |
 Compass Therapeutics, Inc. CMPX | $279M | N/A | — | -$0.42 |
 Crinetics Pharmaceuticals, Inc. CRNX | $3.5B | N/A | — | -$4.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Neuren Pharmaceuticals Limited (NURPF) measures how much investors pay for each dollar of the company's trailing earnings. NURPF's current PE ratio of 55.88x is calculated by dividing its stock price of $9.25 by its TTM earnings per share of $0.24.
Frequently asked questions
NURPF pe ratio · 6 questionsNURPF's current PE ratio is 55.88x as of 2026-06-09, based on a stock price of $9.25 and TTM EPS of $0.24. Data sourced from Financial Modeling Prep via NURPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Neuren Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09